Literature DB >> 8726669

A soluble interleukin 6 receptor isolated from conditioned medium of human breast cancer cells is encoded by a differentially spliced mRNA.

J W Oh1, M Revel, J Chebath.   

Abstract

The human interleukin 6 receptor (IL-6R) is expressed on cells as a transmembrane protein of 80 kDa (gp80, ligand binding unit), or as a smaller soluble counterpart (sIL-6R, approximately 55 kDa). Recombinant or natural sIL-6Rs bind IL-6 and stimulate biological activity by association with the signal transducing subunit gp130 at the cell surface. The origin of sIL-6Rs is not clear. Haematopoietic cells express, in addition to the gp80 mRNA, an IL-6R mRNA where the transmembrane domain is spliced out, predicting a shorter protein with a modified basic sequence at the C-terminus. We show that the spliced mRNA is expressed in human T47D breast carcinoma cells and soluble IL-6R protein is indeed secreted by these cells. An antibody against the C-terminus of the spliced protein detects a 55-65 kDa glycosylated species in sIL-6R purified from T47D supernatant by classical and immunoaffinity chromatography. The spliced T47D IL-6R, glycosylated or after removal of O- and N-linked polysaccharides, has the same size as a recombinant spliced IL-6R from CHO cells. The recombinant spliced IL-6R acts on cells as an IL-6 agonist to stimulate transcription from IL-6 inducible enhancers.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8726669     DOI: 10.1006/cyto.1996.0055

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  8 in total

1.  Test of a novel transparent floating carrier by recombinant cho cells expressing sIL6 receptor protein.

Authors:  D Gurari-Rotman; Z Marks; J Chevath; M Revel; N G Maroudas
Journal:  Cytotechnology       Date:  2001-10       Impact factor: 2.058

Review 2.  Lack of knowledge: breast cancer and the soluble interleukin-6 receptor.

Authors:  Heike Knüpfer; Rainer Preiss
Journal:  Breast Care (Basel)       Date:  2010-06       Impact factor: 2.860

3.  Molecular characterization and expression analysis of the putative interleukin 6 receptor (IL-6Rα and glycoprotein-130) in rainbow trout (Oncorhynchus mykiss): salmonid IL-6Rα possesses a polymorphic N-terminal Ig domain with variable numbers of two repeats.

Authors:  Maria M Costa; Tiehui Wang; Milena M Monte; Christopher J Secombes
Journal:  Immunogenetics       Date:  2011-10-29       Impact factor: 2.846

4.  Interleukin-6 is an autocrine growth factor in human prostate cancer.

Authors:  D Giri; M Ozen; M Ittmann
Journal:  Am J Pathol       Date:  2001-12       Impact factor: 4.307

5.  Shedding of Endogenous Interleukin-6 Receptor (IL-6R) Is Governed by A Disintegrin and Metalloproteinase (ADAM) Proteases while a Full-length IL-6R Isoform Localizes to Circulating Microvesicles.

Authors:  Neele Schumacher; Dörte Meyer; Andre Mauermann; Jan von der Heyde; Janina Wolf; Jeanette Schwarz; Katharina Knittler; Gillian Murphy; Matthias Michalek; Christoph Garbers; Jörg W Bartsch; Songbo Guo; Beate Schacher; Peter Eickholz; Athena Chalaris; Stefan Rose-John; Björn Rabe
Journal:  J Biol Chem       Date:  2015-09-10       Impact factor: 5.157

Review 6.  IL-6/JAK/STAT3 Signaling in Breast Cancer Metastasis: Biology and Treatment.

Authors:  Sara G Manore; Daniel L Doheny; Grace L Wong; Hui-Wen Lo
Journal:  Front Oncol       Date:  2022-03-15       Impact factor: 5.738

7.  Cancer-associated fibroblasts promote endometrial cancer growth via activation of interleukin-6/STAT-3/c-Myc pathway.

Authors:  Kavita S Subramaniam; Intan Sofia Omar; Soke Chee Kwong; Zahurin Mohamed; Yin Ling Woo; Noor Azmi Mat Adenan; Ivy Chung
Journal:  Am J Cancer Res       Date:  2016-01-15       Impact factor: 6.166

8.  Paracrine IL-6 Signaling Confers Proliferation between Heterogeneous Inflammatory Breast Cancer Sub-Clones.

Authors:  Riley J Morrow; Amr H Allam; Belinda Yeo; Siddhartha Deb; Carmel Murone; Elgene Lim; Cameron N Johnstone; Matthias Ernst
Journal:  Cancers (Basel)       Date:  2022-05-04       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.